In 2017, the results of the study of Verger et al. evaluating 43 patients with grade II and III gliomas, conversely showed higher [18F]FDOPA uptake in gliomas with IDH mutation [9]; nevertheless, in the study of Cicone et al. [10], including 33 patients with glioma (grade II, III, and IV gliomas), [18F]FDOPA uptake parameters did not show any correlation with IDH status, with no significant differences between IDH mutant and IDH wild-type gliomas. This evidence concerns the gene IDH1 and central nervous system cancer.